<i>CYP2C9*3</i> gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide - Concepedia

Concepedia

Publication | Closed Access

<i>CYP2C9*3</i> gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide

17

Citations

27

References

2018

Year

Osvaldo D. Castelán-Martínez, Carlos Hoyo‐Vadillo, T. B. Bazán-Soto, Miguel Cruz, Emiliano Tesoro-Cruz, Adán Valladares‐Salgado

Journal of Clinical Pharmacy and Therapeutics

Abstract

The findings suggest that CYP2C9*3 genetic variant independently contributes to good glycaemic control of patients with type 2 diabetes treated with glibenclamide.

References

	Year	Citations

Page 1